Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with 177Lu-PSMA radioligand therapy

被引：8
|
作者：
von Eyben, Finn Edler [1 ]
Kulkarni, Harshad R. [2 ]
Baum, Richard P. [2 ]
机构：
[1] Ctr Tobacco Control Res, Odense, Denmark
[2] Zentralklin Bad Berka, Theranost Ctr Mol Radiotherapy & Mol Imaging, Bad Berka, Germany
来源：
THERANOSTICS | 2020年 / 10卷 / 11期
关键词：
prostate specific membrane antigen; (177)Lutetium [Lu-177]-PSMA radioligand therapy; prostatic neoplasms; restaging; overall survival;
D O I：
10.7150/thno.44568
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
PSMA based radioligand is a new investigational drug for treatment of metastatic multidrug-resistant and castration-resistant prostate cancer. Prognostic factors point to above and below average overall survival (OS) after the treatment. Kessel et al. [Theranostics 2019;9:4841-8] reported for the first time that two sites of visceral metastases, lungs and liver, differed in impact on OS after treatment with Lu-177 PSMA 617. Treatment with established drugs showed the same trend. The difference in OS between the sites is independent of the type of treatment and can reflect changes in tumor biology during the progression of metastatic prostate cancer.
引用
收藏
页码：4900 / 4902
页数：3
相关论文
共 50 条
  • [31] Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
    Bernhard Grubmüller
    Daniela Senn
    Gero Kramer
    Pascal Baltzer
    David D’Andrea
    Karl Hermann Grubmüller
    Markus Mitterhauser
    Harald Eidherr
    Alexander R. Haug
    Wolfgang Wadsak
    Sarah Pfaff
    Shahrokh F. Shariat
    Marcus Hacker
    Markus Hartenbach
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1063 - 1072
  • [32] PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under 177Lu-PSMA-617 Radioligand Therapy
    Widjaja, Liam
    Werner, Rudolf A.
    Ross, Tobias L.
    Bengel, Frank M.
    Derlin, Thorsten
    CANCERS, 2021, 13 (12)
  • [33] PSA flare in patients with metastatic castration-resistant prostate cancer undergoing 177Lu-PSMA treatment.
    Li, Haoran
    Wulff-Burchfield, Elizabeth Marie
    Abbasi, Saqib
    Narang, Arshit
    Dal, Emre
    Donald, Joseph
    Yap, Wendell Y.
    Shen, Xinglei
    Chen, Ronald C.
    Parikh, Rahul Atul
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 157 - 157
  • [34] Therapeutic response and safety of radioligand therapy with 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer patients
    Ashfaq, Wardah
    Rehman, Khurram
    Shahid, Abubaker
    Younis, Muhammad Numair
    MEDICAL ONCOLOGY, 2024, 41 (09)
  • [35] 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney
    Zhang, Jingjing
    Kulkarni, Harshad R.
    Singh, Aviral
    Schuchardt, Christiane
    Niepsch, Karin
    Langbein, Thomas
    Baum, Richard P.
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (11) : 1579 - 1586
  • [36] Radiobiological parameters for the assessment of 177Lu-PSMA-617 Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
    Hu, J.
    Xue, S.
    Mercolli, L.
    Sari, H.
    Rominger, A.
    Afshar-Oromieh, A.
    Shi, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S636 - S636
  • [37] Clinical impact of changes in tumor uptake on PSMAPET/CT during 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer
    Djaileb, L.
    Farolfi, A.
    Rauscher, I.
    Fendler, W.
    Hadaschik, B.
    Rowe, S.
    Herrmann, K.
    Solnes, L.
    Rettig, M.
    Weber, M.
    Czernin, J.
    Calais, J.
    Benz, M.
    Eiber, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S196 - S196
  • [38] Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
    Grubmueller, Bernhard
    Senn, Daniela
    Kramer, Gero
    Baltzer, Pascal
    D'Andrea, David
    Grubmueller, Karl Hermann
    Mitterhauser, Markus
    Eidherr, Harald
    Haug, Alexander R.
    Wadsak, Wolfgang
    Pfaff, Sarah
    Shariat, Shahrokh F.
    Hacker, Marcus
    Hartenbach, Markus
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (05) : 1063 - 1072
  • [39] 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney
    Zhang, Jingjing
    Kulkarni, Harshad
    Singh, Aviral
    Schuchardt, Christiane
    Niepsch, Karin
    Langbein, Thomas
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [40] Rechallenge 177Lu-PSMA radioligand therapy: First assessment in patients with metastatic prostate cancer
    Gafita, A.
    Eiber, M.
    Rauscher, I.
    Retz, M.
    Knorr, K.
    Heck, M.
    Gschwend, J.
    Schwaiger, M.
    Weber, W.
    Tauber, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S587 - S587
12345